Trials / Completed
CompletedNCT03810144
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test on Clinical Outcomes and Pharmaceutical Utilization in Patients With Rheumatoid Arthritis: A Prospective, Randomized Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 444 (actual)
- Sponsor
- Sequenom, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Nine months multi-center prospective, randomized observational study, two arm trial to evaluate the effect of MBDA score-guided care on disease activity and medical costs.
Detailed description
Nine months multi-center prospective, randomized observational study, two arm trial to evaluate the effect of MBDA score-guided care on disease activity and medical costs. To investigate whether treatment decisions guided by MBDA scores result in reduced disease activity and overall medical cost among patients with RA relative to usual care (UC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Vectra MBDA Test | Vectra Guided versus Usual Care |
Timeline
- Start date
- 2018-10-22
- Primary completion
- 2022-08-16
- Completion
- 2022-10-16
- First posted
- 2019-01-18
- Last updated
- 2023-08-09
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03810144. Inclusion in this directory is not an endorsement.